ライフサイエンスコーパス: arterial phase

1 marrow contrast material enhancement in the arterial phase.

2 at enhanced homogeneously during the hepatic arterial phase.

3 portal phase or in the water-fat map in the arterial phase.

4 etector abdominal CT during the late hepatic arterial phase.

5 28 endoleaks were also visualized during the arterial phase.

6 ing was also rated for the each of the three arterial phases.

7 es was superior to that of those obtained in arterial phase (0.63 [19 of 30]) (P < or =.008).

8 d by using combinations of the three phases (arterial, phase 1; peak venous, phase 2; and late venous

9 ined in the hepatic phase (35 HU) and in the arterial phase (25 HU).

10 sent in at least one vessel on 23 of the 105 arterial phase 3D studies.

11 High-quality arterial phase 3D volumetric interpolated breath-hold im

12 of iodinated contrast medium focused on the arterial phase, 64-detector CT angiography allowed satis

13 ic magnetic resonance imaging in the hepatic arterial phase, a timing examination was performed after

14 Use of single-breath-hold multiple arterial phase acquisition in abdominal MR imaging with

15 diagnosis of endoleaks when combined with an arterial phase acquisition.

16 minations included single-breath-hold triple arterial phase acquisition.

17 Arterial phase acquisitions were obtained during suspend

18 de benign nodules with intense uptake in the arterial phase and hepatocellular carcinoma.

19 The number of tumors detected on arterial phase and portal venous phase images and unenha

20 Acquisition of multiple dynamic arterial phase and portal venous phase images increased

21 Arterial phase and portal venous phase pelvic CT angiogr

22 The enhanced CT-measured arterial phase and the venous phase images of kidneys we

23 Cortical volume was calculated from arterial phase and total volume from delayed phase.

24 reviewed in the following combinations: (a) arterial phase and unenhanced scans (uniphasic/unenhance

25 Initial nonenhanced CT was followed by arterial phase and venous phase acquisitions.

26 The CC has minimal or no enhancement on arterial phase and venous phase images but intense enhan

27 cal features of HCC (hypervascularity in the arterial phase and washout in the venous phase) at contr

28 80-kVp acquisition (P < .03) than during the arterial phase and weighted-average venous phase acquisi

29 Dynamic (arterial phase) and steady-state (arterial-venous phase)

30 rpolated breath-hold imaging before, during (arterial phase), and after injection, with thin (2-mm so

31 rt), and SI(del) are tumor SI on unenhanced, arterial phase, and delayed phase three-dimensional T1-w

32 - standard deviation) of 39 HU +/- 13 in the arterial phase, and type B lesions had a difference of -

33 erent radiologist by using true nonenhanced, arterial phase, and venous phase data.

34 ination, including pre-contrast phase (PCP), arterial phase (AP), and portal venous phase (PVP) scans

35 t-enhanced, multi-detector row CT during the arterial phase (AP), pancreatic parenchymal phase (PPP),

36 For the arterial phase at 140 keV, the AUC was 0.94 (95% CI: 0.8

37 ns as adenomas or metastases, except for the arterial phase at 55 KeV, where the area under the recei

38 For the arterial phase at 70 keV, the AUC was 0.76 (95% CI: 0.66

39 the degree of bowel wall enhancement in the arterial phase at contrast-enhanced MR imaging and (b) p

40 and change in bowel wall enhancement in the arterial phase at contrast-enhanced MR imaging over time

41 c resonance angiography during the pulmonary arterial phase at the time of an intravenous bolus of ga

42 Figure 1b: (a) Arterial phase axial CT image at the level of the pancre

43 Figure 1a: (a) Arterial phase axial CT image at the level of the pancre

44 value was statistically significant for the arterial phase between differentiated and undifferentiat

45 sualized the portal phase and the second the arterial phase, both of which are mandatory for liver le

46 In 80% (35 of 44) of subjects, arterial phase breath holds were shorter after gadoxetat

47 Results Arterial phase breath holds were shorter after gadoxetat

48 Arterial phase breath-holding duration and motion artifa

49 bo-controlled trial, whether maximal hepatic arterial phase breath-holding duration is affected by ga

50 Conclusion Maximal hepatic arterial phase breath-holding duration is reduced after

51 Arterial phase breath-holding duration was timed after e

52 igher in attenuation than the thyroid in the arterial phase but were lower in attenuation than the th

53 doxetate from the prebolus phase to the late arterial phase compared with gadoterate (P < .001).

54 Unenhanced and arterial phase computed tomographic (CT) images were acq

55 Baseline arterial phase contrast material-enhanced (CE) MR imagin

56 The authors retrospectively reviewed 186 arterial phase contrast material-enhanced spiral CT scan

57 The authors reviewed arterial phase CT images in 100 consecutive patients wit

58 In 20 (80%) of 25 cases with hepatic arterial phase CT images, all tumors were heterogeneous

59 y be a useful tool for the interpretation of arterial phase CT studies.

60 For parenchymal injury, arterial phase CT was less sensitive (76% [68 of 90] vs

61 At arterial phase CT, enhancement similar to aortic enhance

62 Spectral imaging was used for arterial phase CT.

63 Adding a contrast-enhanced arterial-phase CT acquisition to conventional (18)F-fluo

64 Arterial phase CTA collaterals at presentation were cate

65 re were significantly more severely degraded arterial phase data sets for gadoxetate disodium than fo

66 CT evaluation comprised a standard pulmonary arterial phase dual-energy CT pulmonary angiography acqu

67 For further evaluation, arterial phase ECG-synchronized CT angiography from the

68 For further evaluation, arterial phase ECG-synchronized CT angiography from the

69 Figure 2b: Arterial phase electrocardiography-synchronized CT angio

70 Figure 2c: Arterial phase electrocardiography-synchronized CT angio

71 Figure 2a: Arterial phase electrocardiography-synchronized CT angio

72 between VAS score and MR imaging bowel wall arterial phase enhancement after contrast material admin

73 nal intensity on T1-weighted images, intense arterial phase enhancement after gadolinium injection, a

74 Hepatic arterial phase enhancement of cirrhotic nodules at CT an

75 llular carcinoma (HCC) currently is based on arterial phase enhancement which doesn't take into micro

76 -two percent of the 100 lesions demonstrated arterial phase enhancement.

77 Arterial-phase examinations (defined as relative liver e

78 he central k-space views acquired during the arterial phase for the more proximal stations.

79 At arterial phase gadolinium-enhanced magnetic resonance (M

80 contrast-enhanced MR imaging in the hepatic arterial phase (HAP) and portal venous phase (PVP).

81 l renal masses relative to the cortex in the arterial phase has 100% specificity (95% CI: 84, 100) fo

82 A retrospective review of arterial phase helical computed tomographic (CT) studies

83 Arterial phase helical CT (3-mm collimation, 1-mm recons

84 all pancreatic arteries can be delineated on arterial phase helical CT scans by using optimized techn

85 Two radiologists reviewed 100 consecutive arterial phase helical CT scans of the pancreas in patie

86 Exclusion of rim arterial phase hyperenhancement as a means of satisfying

87 he algorithmic role of tumor in vein and rim arterial phase hyperenhancement improves the diagnostic

88 adiation-based therapies in which persistent arterial phase hyperenhancement in the early posttreatme

89 ICC was 0.87 (95% CI: 0.84, 0.90) for arterial phase hyperenhancement, 0.85 (95% CI: 0.81, 0.8

90 or the three readers were as follows: nonrim arterial phase hyperenhancement, 49%-62% (19-24 of 39 pa

91 Among masses with arterial phase hyperenhancement, the rim pattern was mor

92 Arterial phase images (1.25-mm collimation, 7.5 mm/ 0.8-

93 ase images, portal venous phase plus hepatic arterial phase images (helical biphasic CT), and CTAP pl

94 The arterial phase images also depicted no endoleaks at thes

95 Hepatic arterial phase images and CTAP images, respectively, dep

96 The arterial phase images depicted no additional endoleaks.

97 AI tool PRAEVAorta((R))2 was used to assess arterial phase images for endoleaks.

98 atic arteries were evaluated on the basis of arterial phase images interpreted by two independent rea

99 Eighty-three percent of arterial phase images obtained with automated contrast m

100 Subsequently, arterial phase images were analyzed.

101 sions were seen on CT studies: 48 on hepatic arterial phase images, 49 on portal venous phase phase i

102 al venous phase images, 82 tumors on hepatic arterial phase images, 87 tumors on CTAP images, 87 tumo

103 nenhanced T2-weighted SE images, 92 (84%) on arterial phase images, and 76 (69%) on portal venous pha

104 etal enhancement, marked hyperattenuation on arterial phase images, lymphadenopathy, heterogeneity, e

105 ive review, eight HCCs were detected on only arterial phase images, one on only portal venous phase i

106 mages; 10 were graded as more conspicuous on arterial phase images.

107 on nonenhanced images, and six were seen on arterial phase images.

108 ble at retrospective evaluation, but only on arterial phase images.

109 tient; range, two to 14) with unenhanced and arterial -phase imaging performed between September 2004

110 Arterial phase imaging contributed to a mean of 36.5% of

111 Study results indicate that arterial phase imaging may not be necessary for the rout

112 The addition of hepatic arterial phase imaging to portal venous phase imaging (h

113 For active bleeding, arterial phase imaging was less sensitive (70% [21 of 30

114 For intrasplenic pseudoaneurysm, arterial phase imaging was more sensitive (70% [21 of 30

115 Arterial phase imaging was noncontributory in 22 of 23 c

116 fidence intervals as indicators of how often arterial phase imaging would contribute to the diagnosis

117 examinations, there was 95% confidence that arterial phase imaging would depict an endoleak missed a

118 ntrast-enhanced liver imaging in which early arterial-phase imaging is best for detecting hepatocellu

119 s in 34, heterogeneously hyperattenuating at arterial phase in 38, and hypoattenuating at portal phas

120 Mean motion scores in all three arterial phases in the gadoxetate disodium cohort were s

121 For CT evaluation of blunt splenic injury, arterial phase is superior to portal venous phase imagin

122 Routine acquisition of images in the arterial phase is unnecessary for detection of pancreati

123 The CER of FNH in the arterial phase (mean, 94.3%+/-33.2) was significantly hi

124 Three (7%) of 44 volunteers had severe arterial phase motion artifacts after gadoxetate disodiu

125 SM transient severe motion , based on severe arterial phase motion, despite minimal motion in the oth

126 Renal arterial phase MR angiograms depicted 30 of 31 (97%) sur

127 yspnea that can have a deleterious effect on arterial phase MR image quality and occurs significantly

128 c tumor tissue on contrast material-enhanced arterial phase MR images and the amount of diffusion-res

129 Optimal hepatic arterial phase MR images can be obtained routinely with

130 Arterial phase MR images were assessed quantitatively an

131 igher in attenuation than the thyroid in the arterial phase nor lower in attenuation than the thyroid

132 Reduction in tumor enhancement in the arterial phase occurred immediately after TACE, with a c

133 col B)-were compared during the late hepatic arterial phase of contrast enhancement.

134 cquired sequentially during the late hepatic arterial phase of contrast enhancement.

135 ases a hypervascular appearance in the early arterial phase of contrast-enhancement, with a dynamic e

136 CT angiography, tMIP CT angiography, and the arterial phase of dynamic CT angiography at a vascular c

137 Image quality of the arterial phase of dynamic CT angiography was rated infer

138 ed with standard helical CT angiography, the arterial phase of dynamic CT angiography, and nonfiltere

139 The appearance of hepatic lesions in the arterial phase of enhancement has potential use in the d

140 The arterial phase of image acquisition improves detection o

141 e vascular lesion was visualized only at the arterial phase of image acquisition; the other nine cont

142 f dual-energy CT was lower than those of the arterial phase of perfusion CT (36.1 mGy and 682.3 mGy .

143 differentiation, such as enhancement in the arterial phase (p = 0.032), Wirsung's duct dilatation (p

144 gnificant difference between the enteric and arterial phases (P < .001) but not between the enteric a

145 Arterial phase peak-enhancement is frequently seen in di

146 In the late arterial phase, peritumoral enhancement or the presence

147 enhancing patterns were analysed in the late arterial phase, portovenous phase, and delay phase.

148 red MR angiographic technique, high-quality, arterial phase, relatively motion immune angiograms can

149 10%, P < .0001) and of new severe transient arterial phase respiratory motion-related artifact (18%

150 r and aggregate rate of new severe transient arterial phase respiratory motion-related artifact (scor

151 d with significantly higher incidence of new arterial phase respiratory motion-related artifact compa

152 Frequency of greater new arterial phase respiratory motion-related artifact in ea

153 L) of gadoxetate disodium is associated with arterial phase respiratory motion-related artifact that

154 All cryolesions exhibited arterial phase rim enhancement at CT and MR imaging, and

155 Arterial phase scanning was performed with 1.25-mm secti

156 tion of arteries and of veins was greater on arterial phase scans and on venous phase scans, respecti

157 and hyperattenuating to liver on 106 of 106 arterial phase scans and were isoattenuating to liver on

158 The acquisition of arterial phase scans in addition to venous phase scans d

159 Arterial phase scans were acquired 20-40 seconds after c

160 In the material density maps, in the arterial phase, significant differences were found only

161 rs identified possible or definite tumors on arterial phase studies in 47-50 patients and on venous p

162 T1-weighted fat-saturated, contrast-enhanced arterial-phase T1-weighted fat-saturated, and contrast-e

163 aging with gadoxetate disodium recovers most arterial phases that would otherwise have been compromis

164 nd qualitative data were analyzed during the arterial phase, the enteric phase (which represented pea

165 During arterial phase, the liver enhanced a mean of 29% of the

166 arity relative to the adjacent cortex in the arterial phase, the presence of a capsule, homogeneity,

167 images) for the precontrast phase, the three arterial phases, the portal venous phase, and the late d

168 Imaging included an arterial phase three-dimensional (3D) fat-saturated cont

169 roximately 6 seconds per station, but a long arterial phase time window allowed bolus-chase periphera

170 igher in attenuation than the thyroid in the arterial phase, type B lesions were not higher in attenu

171 Mean CC-SC SI ratios on nonenhanced, arterial phase, venous phase, and delayed phase images w

172 arity relative to the adjacent cortex in the arterial phase was seen in only malignant lesions by bot

173 well as the number of those with "adequate" arterial phases, was compared with the chi(2) or Fisher

174 hree neoplastic lesions seen only during the arterial phase were found in eight patients with concomi

175 tients with nodules that enhanced during the arterial phase were included in the final study group, w

176 nd venous and/or late dynamic phases; >/= 4, arterial phase) were compared (McNemar test).

177 ascular liver tumors during the late hepatic arterial phase while significantly reducing patient radi

178 n CT characteristics: enhancement during the arterial phase, Wirsung's duct dilatation, organ infiltr

179 affected by TSM had at least one well-timed arterial phase with a mean motion score of 3 or less and

180 ak enhancement of the osteoid osteoma in the arterial phase with early partial washout, compared with